Overview of Pharmacovigilance Inspection in UK

Abstract

Abstract: To promote pharmaceutical manufacturer, the first person for products safety to undertake post-marketing surveillance responsibility,UK initiated pharmacovigilance inspection programme in 2003, and now it formed a set of complete inspection system.This article introduced pharmacovigilance inspection type, process, findings and so on in UK, and proposed recommendation on adverse drug reaction report and monitoring inspection responsiblity division, guideline, self-checking indicatior system and information communication.

Key words: UK, pharmacovigilance, adverse drug reaction, inspection

CLC Number:

R951

DONG Duo, WU Gui-zhi, WANG Dan, FENG Hong-yun, WANG Ya-li, CHENG Gang. Overview of Pharmacovigilance Inspection in UK[J]. Chinese Journal of Pharmacovigilance, 2014, 11(8): 478-481.

References

[1] MHRA. Guidance Notes on the Information Requested For an MHRAStatutory Pharmacovigilance Inspection [EB/OL].(2013-04-01)[2014-07-22].http://www.mhra.gov.uk/home/groups/is-insp/
documents/websiteresources/con057172.pdf .
[2] 新浪财经.罗氏不良反应事件大量数据仍未公开[EB/OL].(2012-07-16])[2014-07-22].http://finance.sina.com.cn/roll/20120716/072512573757.shtml.
[3] 国家食品药品监督管理局.《药品不良反应报告和监测管理办法》修订发布[EB/OL].（2011-5-24）[2014-07-22]. http://www.sda.gov.cn/WS01/CL0051/62634.html.
[4] MHRA. Types of inspections [EB/OL].（2013-07-18）[2014-07-22].http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodPharmacovigilancePrac.
[5] 董铎,孙立华,杨晓茹.欧盟药物警戒检查制度简介[J]. 中国新药杂志, 2012,21(8):832-835.
[6] MHRA.GoodPharmacovigilance Practice: TheInspection Process [EB/OL].（2013-07-18）[2014-07-22].http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodPharmacovigilancePractice/Theinspectionprocess/index.htm(2014-07-22).
[7] MHRA.Overview of the Pharmacovigilance Inspection Progress [EB/OL].（2008-02-04）[2014-07-22].http://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con013899.pps.
[8] MHRA.Part II:SPS Template[EB/OL]. (2010-10-01)[2014-07-22].http://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con2018030.doc.
[9] MHRA.Frequently asked questions for Good Pharmacovigilance Practice[EB/OL].（2013-09-24）[2014-07-22].http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodPha-rmacovigilancePractice/Frequentlyaskedquestions/index.htm#5.
[10] MHRA. Inspection report and company response process[EB/OL].[2014-07-22].http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodPharmacovigilancePractice/Theinspectionprocess/index.htm.
[11] MHRA.Responding to inspection findings [EB/OL]. (2013-01-01)[2014-07-22].http://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con013900.ppt.
[12] MHRA.Grading of inspection findings[EB/OL].（2013-07-18）[2014-07-22].http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodPharmacovigilancePractice/Theinspectionprocess/index.htm.
[13] MHRA.Pharmacovigilance inspection metrics[EB/OL].（2013-07-18）[2014-07-22].http://www.mhra.gov.uk/Howweregulate/Med-icines/Inspectionandstandards/GoodPharmacovigilancePractice/Pharmacovigilanceinspectionmetrics/index.htm.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[10]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[11]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[12]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[13]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[14]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[15]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.